Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:EXDI OTCMKTS:IMUC NASDAQ:ITRM NASDAQ:KALA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEXDIExactus$0.00$0.04▼$0.27$38.94M4.2183,144 shs257,300 shsIMUCEOM Pharmaceutical$0.10$0.09$0.01▼$0.21$12.65M-0.012,307 shs2,153 shsITRMIterum Therapeutics$0.80-2.7%$0.97$0.80▼$3.02$33M2.79737,083 shs873,135 shsKALAKALA BIO$8.09+15.6%$4.80$2.92▼$11.20$45.17M-1.88177,006 shs432,545 shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEXDIExactus0.00%0.00%0.00%0.00%0.00%IMUCEOM Pharmaceutical0.00%+25.00%-1.67%-27.38%-40.79%ITRMIterum Therapeutics-2.73%-12.45%-22.09%-36.31%-36.06%KALAKALA BIO+15.57%+40.94%+72.13%+154.40%+15.24%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEXDIExactusN/AN/AN/AN/AN/AN/AN/AN/AIMUCEOM PharmaceuticalN/AN/AN/AN/AN/AN/AN/AN/AITRMIterum Therapeutics2.0519 of 5 stars3.53.00.00.03.30.00.0KALAKALA BIO3.9102 of 5 stars3.52.00.04.42.30.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEXDIExactus 0.00N/AN/AN/AIMUCEOM Pharmaceutical 0.00N/AN/AN/AITRMIterum Therapeutics 3.00Buy$9.001,021.50% UpsideKALAKALA BIO 3.00Buy$13.0060.69% UpsideCurrent Analyst Ratings BreakdownLatest IMUC, EXDI, ITRM, and KALA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/11/2025KALAKALA BIOLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.006/2/2025KALAKALA BIOOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$15.005/23/2025KALAKALA BIOHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $12.005/8/2025ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$9.00(Data available from 7/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEXDIExactus$2.07M0.00N/AN/A($0.09) per share0.00IMUCEOM PharmaceuticalN/AN/AN/AN/AN/AN/AITRMIterum TherapeuticsN/AN/AN/AN/A($0.15) per shareN/AKALAKALA BIO$3.89M13.41N/AN/A$2.02 per share4.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEXDIExactus-$9.46MN/AN/AN/AN/AN/A-3,272.69%-185.29%N/AIMUCEOM Pharmaceutical-$1.89MN/A0.00∞N/AN/AN/AN/AN/AITRMIterum Therapeutics-$24.77M-$0.99N/A∞N/AN/AN/A-71.37%8/13/2025 (Estimated)KALAKALA BIO-$38.51M-$8.24N/AN/AN/AN/A-369.29%-64.99%8/5/2025 (Estimated)Latest IMUC, EXDI, ITRM, and KALA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025ITRMIterum Therapeutics-$0.13N/AN/AN/AN/AN/A8/5/2025Q2 2025KALAKALA BIO-$1.82N/AN/AN/AN/AN/A5/13/2025Q1 2025ITRMIterum Therapeutics-$0.14-$0.14N/A-$0.14N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEXDIExactusN/AN/AN/AN/AN/AIMUCEOM PharmaceuticalN/AN/AN/AN/AN/AITRMIterum TherapeuticsN/AN/AN/AN/AN/AKALAKALA BION/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEXDIExactusN/A1.320.82IMUCEOM PharmaceuticalN/AN/AN/AITRMIterum TherapeuticsN/A3.723.58KALAKALA BIO3.191.991.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEXDIExactus0.12%IMUCEOM PharmaceuticalN/AITRMIterum Therapeutics9.21%KALAKALA BIO24.61%Insider OwnershipCompanyInsider OwnershipEXDIExactus65.00%IMUCEOM Pharmaceutical3.28%ITRMIterum Therapeutics9.20%KALAKALA BIO8.32%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEXDIExactus30599.01 million209.65 millionNot OptionableIMUCEOM Pharmaceutical3126.50 million122.35 millionNot OptionableITRMIterum Therapeutics1040.00 million36.32 millionNot OptionableKALAKALA BIO306.45 million5.92 millionNot OptionableIMUC, EXDI, ITRM, and KALA HeadlinesRecent News About These CompaniesAnalyst Coverage Sparks Interest in These 4 Stocks Amid VolatilityJuly 25 at 12:56 PM | zacks.comKALA BIO (NASDAQ:KALA) Stock Rating Lowered by Wall Street ZenJuly 22, 2025 | americanbankingnews.comKALA Bio completes enrollment of CHASE clinical trialJuly 12, 2025 | ophthalmologytimes.comOKALA BIO Announces Completion of Enrollment in CHASE Clinical Trial ...July 11, 2025 | morningstar.comMKALA BIO Completes Patient Enrollment in CHASE Phase 2b Trial ... - NasdaqJuly 11, 2025 | nasdaq.comKALA BIO Inc. (KALA) Stock Price Today - WSJ - The Wall Street JournalJuly 10, 2025 | wsj.comKALA BIO, Inc.: KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)July 9, 2025 | finanznachrichten.deKala Pharmaceuticals Completes Enrollment for Phase 2b TrialJuly 9, 2025 | tipranks.comKALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)July 9, 2025 | globenewswire.comKala Bio Inc Valuation - MorningstarJuly 8, 2025 | morningstar.comMKALA BIO, Inc. (KALA) - Yahoo FinanceJuly 1, 2025 | finance.yahoo.comKALA BIO, Inc. (NASDAQ:KALA) CFO Sells $14,560.31 in StockJune 27, 2025 | insidertrades.comMary Reumuth Sells 2,850 Shares of KALA BIO, Inc. (NASDAQ:KALA) StockJune 5, 2025 | insidertrades.comKALA BIO to Present at Jefferies Global Healthcare ConferenceMay 29, 2025 | globenewswire.comKALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 14, 2025 | finance.yahoo.comChief Minister cancels programme over unauthorised nature of venueApril 20, 2025 | thehindu.comKALA BIO: Q4 Earnings SnapshotMarch 31, 2025 | timesunion.comTKALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateMarch 31, 2025 | markets.businessinsider.comKALA BIO to Present at TD Cowen 45th Annual Health Care ConferenceFebruary 26, 2025 | finance.yahoo.comKala Bio announces CEO departure, appoints interim leaderFebruary 12, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMUC, EXDI, ITRM, and KALA Company DescriptionsExactus OTCMKTS:EXDIExactus, Inc., is a farmer and manufacturer of hemp-derived phytocannabinoid products. The company sells its CBD products through its Green Goddess brand and third-party resellers. Exactus is engaged in producing industrial hemp from farms in Oregon and plans to extract and manufacture directly through cGMP facilities. Industrial hemp is a type of cannabis, defined by the federal government as having THC (tetrahydrocannabinol) content of 0.3 percent or less. THC is the psychoactive compound found in cannabis.EOM Pharmaceutical OTCMKTS:IMUC$0.10 0.00 (0.00%) As of 07/24/2025 01:38 PM EasternImmunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.Iterum Therapeutics NASDAQ:ITRM$0.80 -0.02 (-2.73%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$0.81 +0.01 (+1.43%) As of 07/25/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.KALA BIO NASDAQ:KALA$8.09 +1.09 (+15.57%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$8.14 +0.04 (+0.56%) As of 07/25/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Intel's Turnaround Gains Credibility With Strong Q2 Report Qualcomm's Next Gear: A Growth Story Wall Street Might Be Missing Krispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat? From Zero to Hero? Why GoPro's Rally Could Be More Than It Seems CrowdStrike Scores Big With Gartner, But Valuation Is Stretched ServiceNow: The 2nd Wave of AI Spending Is Here Tractor Supply Revs Up on Forecast Hike and Bullish Signals A Smokin’ Hot Entry Point for Chipotle Stock Opens in Q3 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
